Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide
NCT00134004Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2004
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in hematologic malignancy, acute leukemia, chronic myelogenous leukemia (CML) and 7 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Transplant-related Mortality at 11 years, Relapse Rate at 11 years and 1 more. Started Oct 2004; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematologic malignancyacute leukemiachronic myelogenous leukemia (CML)chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00134004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134004.